No Data
No Data
Milestone Pharmaceuticals to Host KOL Event for Investors "Learnings From the Field: Expert Perspectives on PSVT in the Community Setting" on June 20, 2024
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat
It Looks Like Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO May Expect Their Salary To Be Put Under The Microscope
Milestone Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare
Strong Buy Rating for Milestone Pharmaceuticals Amidst Promising CARDAMYST Prospects and Market Strategy
Express News | FDA Accepts Milestone Pharmaceuticals' New Drug Application For Cardamyst (Etripamil) Nasal Spray, To Manage Paroxysmal Supraventricular Tachycardia Prescription Drug User Fee Act Is 10 Months From The Acceptance Date Of May 26, 2024
Express News | Milestone Pharmaceuticals Inc: FDA Prescription Drug User Fee Act (Pdufa) Target Date Is 10 Months From Acceptance Date of May 26, 2024.
No Data